No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
BIO240517C290000
- 2.00
- +1.70+566.67%
15min DelayClose May 10 16:00 ET
3.80High2.00Low
3.80Open0.30Pre Close4 Volume13 Open Interest290.00Strike Price1.16KTurnover35.38%IV3.68%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier6DDays to Expiry2.00Time Value100Contract SizeAmericanOptions Type0.2913Delta0.0258Gamma118.74Leverage Ratio-0.3718Theta0.0142Rho34.59Eff Leverage0.1290Vega
Intraday
- 5D
- 1D
News
Bio-Rad Laboratories | 10-Q: Quarterly report
The Analyst Landscape: 4 Takes On Bio-Rad Laboratories
Bio-Rad Laboratories (NYSE:BIO) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The following table summarizes their recent
UBS Adjusts Price Target on Bio-Rad Laboratories to $385 From $420, Maintains Buy Rating
Bio-Rad Laboratories (BIO) has an average outperform rating and price target range of $365 to $441, according to analysts polled by Capital IQ. Price: 271.46, Change: -8.45, Percent Change: -3.02
Express News | Bio Rad Laboratories Inc : UBS Cuts Target Price to $385 From $420
Bio-Rad Laboratories Price Target Cut to $385.00/Share From $420.00 by UBS
Bio-Rad Laboratories Price Target Cut to $385.00/Share From $420.00 by UBS
Bio-Rad Laboratories Is Maintained at Buy by UBS
Bio-Rad Laboratories Is Maintained at Buy by UBS
Comments
$Sunshine Biopharma(SBFM.US$ SHORTS time to say hello to my little friend $Bio-Rad Laboratories(BIO.US$
Despite a superior revenue outlook, the company isn't trading at a higher P/S due to potential risks like not meeting analysts' revenue projections in tough industry conditions. Investors anticipate future revenue volatility.
Bio-Rad's unstable profits and stale growth over the past three years are worrying. Despite a rise in stocks, long-term performance lacks strength. If fundamentals signal sustainable growth, the current sell-off could be a chance.
Here are the top gap ups and downs for the stocks with a market cap above $5 billion after the previous market closed (gaps range from large to small):
Gap Ups
1. $Live Nation Entertainment(LYV.US$ - up 9.3%
2. $BILL Holdings(BILL.US$ - up 8.7%
3. $Coinbase(COIN.US$ - up 6.5%
4. $DraftKings(DKNG.US$ - up 6.2%
5. $Apellis Pharmaceuticals(APLS.US$ - up 5.3%
6. $Reinsurance Group of America(RGA.US$ - up 3.9%
7. $Equinor(EQNR.US$ - up 3.7...
Gap Ups
1. $Live Nation Entertainment(LYV.US$ - up 9.3%
2. $BILL Holdings(BILL.US$ - up 8.7%
3. $Coinbase(COIN.US$ - up 6.5%
4. $DraftKings(DKNG.US$ - up 6.2%
5. $Apellis Pharmaceuticals(APLS.US$ - up 5.3%
6. $Reinsurance Group of America(RGA.US$ - up 3.9%
7. $Equinor(EQNR.US$ - up 3.7...
+16
16
2
Read more